Current Perspective for Cardiac Magnetic Resonance Imaging in Heart Failure

Login or register to view PDF.
Asia Pacific Cardiology - Volume 1 Issue 1;2007:1(1):27-28


Despite advances in the diagnosis and management of coronary artery disease (CAD) in developed countries, a significant proportion of CAD patients develop heart failure, which is associated with a tremendous economic and societal burden.1,2 With increasing industrialisation, changes in diet and a rapidly ageing population, there has been an enormous increase in the prevalence of heart failure due to CAD in South Asia and China. This has led to huge healthcare expenditure each year in these developing countries.3 It is well-known that heart failure progresses through different stages, and optimal medical therapy in the early stage of disease can slow its progression.4 Furthermore, early diagnosis and recognition of reversible elements that lead to heart failure can further improve long-term outcome. Cardiac magnetic resonance imaging (cMRI) is unique in that it has an unlimited imaging window, free from radiation exposure, little inter- and intra-observer variability and excellent tissue characterisation. This article reviews the current role of cMRI in the diagnosis and management of ischaemic cardiomyopathy.

Myocardial Function

Previous clinical studies have shown that assessment of left ventricular (LV) function provides important information and is a powerful independent prognostic index for patients with heart failure.5 Currently, transthoraic echocardiography is the most widely used technique for measuring LV chamber dimension and function as it is easily available. Nevertheless, it is limited by several technical problems, including poor echo windows, unclear endocardial definition and unusual chamber geometry in some patients, which causes significant inter- and intra-observer variability. In contrast, cMRI provides highly reproducible LV volumetric measurements due to unlimited imaging windows and the high tissue contrast between the endocardial border and the blood pool.6 Furthemore, cMRI acquires chamber volumes in a 3D fashion. The endocardial contours at the end-systolic and end-diastolic phase of each contiguous LV short-axis level of the whole heart are traced manually. The chamber volumes are obtained simply by adding the volume of all of the slice levels. As a result, unlike echocardiography, no geometry assumption is required. Since cMRI is more sensitive in detecting the temporal changes in myocardial size, mass and function, it has been increasingly used in clinical practice and trials for the assessment of disease progression as well as the response to therapy. In addition, by using semi-quantitative methods (American College of Cardiologists [ACC]/American Heart Association [AHA] 17 Segments Guideline), the functional recovery regarding regional wall contractility can be compared in patients with CAD before and after revascularisation.7


  1. American Heart Association, Heart and Stroke Statistical Update. American Heart Association, 2001.
  2. Haldeman GA, Croft JB, Giles WH, Rashidee A, Hospitalisation of patients with heart failure: National hospital discharge survey, 1985–1995, Am Heart J, 1999;137:352–60.
  3. Yusuf S, et al., Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors and impact of urbanisation, Circulation, 2001;104:2746–53.
  4. Hunt SA, Abraham WT, et al., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), J Am Coll Cardiol, 2005;46:e1–82.
  5. Rogers WA, et al., on behalf of the SOLVD investigators. Studies of left ventricular dysfunction, Am J Cardiol, 1990;66:315–22.
  6. Semelka RC, Tomei E, et al., Interstudy variability in left ventricular mass measurement. Comparison between m-mode echocardiography and MRI, Eur Heart J, 1992;13:1011–19.
  7. Schiller NB, Shah PM, et al., American Society of Echocardiography Committee on Standards Subcommittee on Quantitation of Two Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography, J American Soc Echocardio, 1989;2:358–67.
  8. Froelicher VF, Lehmann KG, et al., The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerised interpretation and multivariable prediction, Ann Intern Med, 1998;128:965–74.
  9. Garber AM, Solomon NA, Cost effectiveness of alternative test strategies for the diagnosis of coronary artery disease, Ann Intern Med, 1999;130:719–28.
  10. Al-Saadi N, Nagel E, et al., Non-invasive detection of myocardial ischaemia from perfusion reserve based on cardiovascular magnetic resonance, Circulation, 2000;101:1379–83.
  11. Hundley WG, et al., Magnetic resonance imaging determination of cardiac prognosis, Circulation, 2002;106:2328–33.
  12. Allman KC, Shaw LJ, Hachamovitch R, et al., Myocardial viability testing and impact of revascularisation on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis, J Am Coll Cardiol, 2002;39:1151–8.
  13. Mickleborough LL, et al., Results of revascularisation in patients with severe left ventricular dysfunction, Circulation, 1995;92:II73–9.
  14. Jansen MA, Van Emous JG, Nederhoff MG, et al., Assessment of myocardial viability by intracellular 23 Na magnetic resonance imaging, Circulation, 2004;110:3457–64.
  15. Kim RJ, et al., The use of contrast-enhanced MRI to identify reversible myocardial dysfunction, N Engl J Med, 2000;343:1445–53.
  16. Ibrahim T, et al., Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computer tomography for detection of myocardial necrosis early after acute myocardial infarction, J Am Coll Cardiol, 2007;49:208–16.
  17. Kim RJ, Fieno DS, Parrish RB, et al., Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age and contractile function, Circulation, 1999;100:185–92.
  18. Kwong RY, Chan AK, et al., Impact of unrecognised myocardial scar detected by cardiac magnetic resonance imaging on eventfree survival in patients presenting with signs or symptoms of coronary artery disease, Circulation, 2006;113:2733–43.
  19. Sogarrd, Egebald H, et al., Sequential versus simultaneous biventricular resynchronisation for severe heart failure: Evaluation by Tissue Doppler imaging, Circulation, 2002;106:2078–84.
  20. Bristow MR, et al., Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 2004;350:2140–50.
  21. Cleland J, et al., The effect of cardiac resynchronisation on morbidity and mortality in heart failure, N Eng J Med, 2005;352:1539–49.
  22. Axel L, Dougherty L, MRI imaging of motion with spatial modulation of magnetisation, Radiology, 1989;171:841–5.
  23. Zerhouni EA, Parish DM, Rogers WJ, et al., Human heart: tagging with MRI a method for non-invasive assessment of myocardial motion, Radiology, 1988:169:59–63.
  24. Edvardsen T, Gerber BL, Garot J, et al., Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against 3D tagged magnetic resonance imaging, Circulation, 2002;106:50–56.
  25. Castillo E, et al., Quantitative assessment of regional myocardial function with MRI-tagging in a multicentre study: interobserver and intraobserver agreement of fast strain analysis with Harmonic Phase (HARP) MRI, J Cardiovasc Magn Reson, 2005;7:783–91.
  26. Penicka M, et al., Improvement of left ventricular function after cardiac resynchronisation therapy is predicted by tissue Doppler imaging echocardiography, Circulation, 2004;109:978–83.
  27. White AJ, Yee R, Yuan X, et al., Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronisation therapy in patients with intraventricular dyssynchrony, J Am Coll Cardiol, 2006;48:1953–60.
  28. Bleeker GB, et al., Effect of post-erolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronisation therapy, Circulation, 2006;113:969–76.
  29. Tse HF, Yiu KH, Lau CP, Bone marrow stem cell therapy for myocardial angiogenesis, Curr Vasc Pharmacol, 2007;5:103–112.
  30. Beeres SL, Bengel FM, Bartunek J, et al., Role of imaging in cardiac stem cell therapy, JACC, 2007;49:1137–48.